- About Us
- Advisory Board
- Editorial
- Contact Us
- Advertise
- Contact MJH LS
- Do Not Sell My Information
- Terms and Conditions
- Privacy
© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
Bruce Cree, MD, PhD, MAS, FAAN
Articles
Role of Serum Neurofilament Light in Predicting Neuromyelitis Optica Attacks: Bruce Cree, MD, PhD, MAS, FAAN
November 08, 2022
Video
The clinical research director of the UCSF Multiple Sclerosis Center provided perspective on the importance of serum neurofilament light and how it can be used in the management of patients with NMOSD. [WATCH TIME: 3 minutes]
Emerging Biomarkers to Consider for NMOSD, Neuromyeltis Optica: Bruce Cree, MD, PhD, MAS, FAAN
November 03, 2022
Video
The clinical research director of the UCSF Multiple Sclerosis Center discussed the need for measures of progression in neuromyelitis optica and the next steps in treatment. [WATCH TIME: 4 minutes]
Inebilizumab’s Impact on B-Cells, Plasmablasts, and Plasma Cells in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
November 02, 2022
Video
The clinical research director of the UCSF Multiple Sclerosis Center provided insight on an abstract from ECTRIMS 2022 regarding inebilizumab’s mechanism of action to prevent NMOSD attacks. [WATCH TIME: 3 minutes]
Ublixtumab’s Effect on Measures of MS Disability: Bruce Cree, MD, PhD, MAS, FAAN
April 17, 2022
Video
The clinical research director of the UCSF Multiple Sclerosis Center discussed the recently presented analysis on ublituximab’s effect on disability in relapsing MS and the critical need to focus on improving quality of life. [WATCH TIME: 4 minutes]
Multiple Sclerosis Disability Improvements With Ublituximab
April 15, 2022
Video
Bruce Cree, MD, PhD, MAS, FAAN, shared his thoughts on the data from the ULTIMATE I and II studies of ublituximab's effect on measures of MS disability, including EDSS and 9HPT scores.
The Therapeutic Advances in Efficacy for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
April 07, 2022
Video
The clinical research director of the UCSF Multiple Sclerosis Center offer his perspective on the 3 available agents for the treatment of patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 2 minutes]
Inebilizumab’s Efficacy in Patients With NMOSD Early in Disease Course: Bruce Cree, MD, PhD, MAS, FAAN
April 04, 2022
Video
The clinical research director of the UCSF Multiple Sclerosis Center discussed new data presented at AAN on inebilizumab (Uplizna; Horizon) in neuromyelitis optica spectrum disorder. [WATCH TIME: 4 minutes]
New Sponsors, Potential Development in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
October 24, 2021
Video
Following the approval of 3 treatments for the disease, the clinical research director of the UCSF Multiple Sclerosis Center commented on the implications for the clinical development pipeline. [WATCH TIME: 4 minutes]
Patient Education and Awareness in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
October 13, 2021
Video
The clinical research director of the USCF Multiple Sclerosis Center discussed the importance of improving knowledge and education for patients with NMOSD, as well as strategies to do so. [WATCH TIME: 3 minutes]
Day-to-Day Care of NMOSD, Advances and Challenges: Bruce Cree, MD, PhD, MAS, FAAN
October 12, 2021
Video
Discussing the 3 FDA-approved treatments for NMOSD, the clinical research director of the UCSF Multiple Sclerosis Center commented on the positive impact, as well as resultant barriers to care. [WATCH TIME: 4 minutes]
Latest News
Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses
Digital Treatment Approach May Help Reduce Healthcare Burden for MS Fatigue: Federica Picariello, PhD
CGRP Antagonist Atogepant Improves Patient-Reported Outcomes as Migraine Preventive
Using Nonpharmacological Interventions to Promote Healthier Lifestyles in Multiple Sclerosis